View clinical trials related to Neoplasm of Bone.
Filter by:GSK-3β is a potentially important therapeutic target in human malignancies. The Actuate 1801 Phase 1/2 study is designed to evaluate the safety and efficacy of 9-ING-41, a potent GSK-3β inhibitor, as a single agent and in combination with cytotoxic agents, in patients with refractory cancers.
To evaluate the safety and efficacy of patients with recurrent and metastatic bone tumors.
Registration of all sarcoma patients treated at a specialized sarcoma center in Switzerland.